BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30231353)

  • 1. Moving From Mutation to Actionability.
    Colombo I; Kurnit KC; Westin SN; Oza AM
    Am Soc Clin Oncol Educ Book; 2018 May; 38():495-503. PubMed ID: 30231353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic insights in gynecologic cancer.
    Roddy E; Chapman J
    Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor-Agnostic Drug Development.
    Offin M; Liu D; Drilon A
    Am Soc Clin Oncol Educ Book; 2018 May; 38():184-187. PubMed ID: 30231313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Obstet Gynecol Clin North Am; 2019 Mar; 46(1):155-163. PubMed ID: 30683261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
    Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
    BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
    Mosely SI; Prime JE; Sainson RC; Koopmann JO; Wang DY; Greenawalt DM; Ahdesmaki MJ; Leyland R; Mullins S; Pacelli L; Marcus D; Anderton J; Watkins A; Coates Ulrichsen J; Brohawn P; Higgs BW; McCourt M; Jones H; Harper JA; Morrow M; Valge-Archer V; Stewart R; Dovedi SJ; Wilkinson RW
    Cancer Immunol Res; 2017 Jan; 5(1):29-41. PubMed ID: 27923825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing Genome-Driven Oncology.
    Hyman DM; Taylor BS; Baselga J
    Cell; 2017 Feb; 168(4):584-599. PubMed ID: 28187282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
    Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
    BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
    Baretti M; Azad NS
    Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.
    Tanabe Y; Ichikawa H; Kohno T; Yoshida H; Kubo T; Kato M; Iwasa S; Ochiai A; Yamamoto N; Fujiwara Y; Tamura K
    Mol Cancer; 2016 Nov; 15(1):73. PubMed ID: 27852271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
    Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
    Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Barroilhet L; Matulonis U
    Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise of genomic profiling in ovarian cancer.
    Previs RA; Sood AK; Mills GB; Westin SN
    Expert Rev Mol Diagn; 2016 Dec; 16(12):1337-1351. PubMed ID: 27828713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
    Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.